Nn-220 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 78 | Hypopituitarism | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00184743 (ClinicalTrials.gov) | December 6, 2003 | 13/9/2005 | Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) | Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency | Growth Hormone Disorder;Adult Growth Hormone Deficiency | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | 18 Years | 65 Years | All | 112 | Phase 3 | Japan |
| 2 | NCT00519558 (ClinicalTrials.gov) | May 31, 2003 | 20/8/2007 | Growth Hormone Deficiency in Adults (GHDA) | Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency | Growth Hormone Disorder;Adult Growth Hormone Deficiency | Drug: somatropin | Novo Nordisk A/S | NULL | Completed | 18 Years | 65 Years | All | 121 | Phase 3 | Japan |
| 3 | EUCTR2017-000914-47-Outside-EU/EEA (EUCTR) | 23/05/2017 | Growth hormone treatment in children born small for gestational age (SGA) | A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for gestational ageExtension to trial GHLiquid-1516: A 104-week, multi-centre, randomised, double-blind, parallel-group, no treatment controlled (open-label) trial investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for gestational age | Foetal growth problemSmall for Gestational AgeGrowth hormone deficiency in children MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: NN-220 INN or Proposed INN: SOMATROPIN Other descriptive name: SOMATROPIN Product Name: NN-220 INN or Proposed INN: SOMATROPIN Other descriptive name: SOMATROPIN | Novo Nordisk A/S | NULL | NA | Female: yes Male: yes | 86 | Phase 3 | Japan |